DMTK News and Press, DermTech Inc From 07/12/23

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximat...

2023-06-29 10:10:59 ET Gainers: RenovoRx ( RNXT ) +37% . Immunome ( IMNM ) +36% .  DermTech ( DMTK ) +15% . Galera Therapeutics ( GRTX ) +9% . Oncolytics Biotech ( ONCY ) +7% . Losers: BioXcel Therapeutics ( BTA...

2023-06-28 17:04:56 ET DermTech ( NASDAQ: DMTK ) said on Wednesday that it would suspending all of its pipeline programs, and focusing its resources on increasing DermTech Melanoma Test (DMT) billable samples and expanding payer coverage. The company's shares ...

- Strategic focus on growing revenue for the DermTech Melanoma Test (DMT) - Annualized cost reduction of between $25 million and $30 million - Cash runway extended into the first quarter of 2025 DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in preci...

2023-06-20 05:25:00 ET Nano-X Imaging (NASDAQ: NNOX) , DermTech (NASDAQ: DMTK) , and Viking Therapeutics (NASDAQ: VKTX) are healthcare growth stocks with plenty of potential, little revenue, and a boatload of risk. Share prices of Nano-X are up more than 150%...

2023-06-20 04:20:22 ET Summary DermTech has appointed a new CEO, Bret Christensen, who faces the challenge of commercializing the company's SmartSticker solution and increasing sales momentum. The company needs to address its high SG&A expenses and total losses, as well as sec...

- Health insurance plans and health systems use ECRI’s technology reviews to formulate coverage policies and clinical protocols DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive s...

2023-06-07 09:06:57 ET Molecular diagnostic company DermTech ( NASDAQ: DMTK ) shares jumps 7.6% premarket on Wednesday after it signs a contract with a Blues plan in Hawaii. In addition to a favorable coverage policy, the contract enhances access to the found...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy,...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT use...